Description: Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The company's NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor and brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. It is developing NurOwn, an autologous adult stem cell product for the treatment of ALS. Brainstorm Cell Therapeutics Inc. also has agreements with Hadasit Medical Research Services and Development Ltd. to conduct its ALS clinical trials at the Hadassah Medical Center. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics was founded in 2000 and is based in New York, New York.
Home Page: www.brainstorm-cell.com
BCLI Technical Analysis
1325 Avenue of Americas
New York,
NY
10019
United States
Phone:
201 488 0460
Officers
| Name | Title |
|---|---|
| Mr. Chaim Lebovits | Chief Exec. Officer |
| Dr. Irit Arbel DSc, Ph.D. | Co-Founder & Independent Vice Chair of the Board |
| Dr. Ralph Z. Kern | Pres & Chief Medical Officer |
| Dr. Stacy R. Lindborg Ph.D. | Exec. VP & Chief Devel. Officer |
| Mr. Uri Yablonka | Exec. VP, Chief Bus. Officer, Sec. & Director |
| Ms. Alla Patlis CPA, M.B.A. | Controller & Interim CFO |
| Dr. David Setboun M.B.A., Pharm.D. | Exec. VP & COO |
| Dr. Yael Gothelf | VP of Scientific & Regulatory Affairs |
| Ms. Antal Pearl-Lendner | VP & Chief Legal Counsel |
| Dr. Daniel Offen Ph.D. | Chief Scientific Advisor |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 47.3885 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2003-08-28 |
| Fiscal Year End: | December |
| Full Time Employees: | 43 |